

COUNSELLORS AT LAW 28 STATE STREET BOSTON, MASSACHUSETTS 02109-1784 TELEPHONE (617) 227-7400 FAX (617) 742-4214 lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997) THOMAS V. SMURZYNSKI RALPH A. LOREN GIULIO A. DeCONTI, JR. ANN LAMPORT HAMMITTE ELIZABETH A. HANLEY **AMY BAKER MANDRAGOURAS** ANTHONY A. LAURENTANO **KEVIN J. CANNING** JANE E. REMILLARD DEANN FORAN SMITH PETER C. LAURO DEBRA J. MILASINCIC, Ph.D. DAVID J. RIKKERS DAVID R. BURNS JOHN S. CURRAN SEAN D. DETWEILER MEGAN E. WILLIAMS, Ph.D.

LISA M. DIROCCO HATHAWAY P. RUSSELL \* MARIA LACCOTRIPE ZACHARAKIS, Ph.D. VINCENT P. LOCCISANO MERIDETH C. ARNOLD DANIELLE L. HERRITT **EUIHOON LEE \*\*** 

SENIOR COUNSEL JAMES E. COCKFIELD

OF COUNSEL JEREMIAH LYNCH WILLIAM A. SCOFIELD, JR. SIBLEY P. REPPERT JEANNE M. DIGIORGIO CYNTHIA L. KANIK, Ph.D.

**PATENT AGENTS** THEODORE R. WEST CYNTHIA M. SOROOS PETER W. DINI, Ph.D. JONATHAN M. SPARKS, Ph.D.

**TECHNICAL SPECIALISTS** CATHERINE M. BISHOP JACOB G. WEINTRAUB CRISTIN E. HOWLEY, Ph.D. JILL ANN MELLO, Ph.D. DEBORAH L. NAGLE, Ph.D. A. JACQUELINE NOWAK, PH.D. ANDRINA WILLIAMS ZINK

\* Admitted in TX only

\*\* Admitted in CT only

## RECEIVED

JUL 0 9 2003

**TECH CENTER 1600/2900** 

July 1, 2003

Commissioner for Patents Post Office Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Patent Application Serial No. 10/010,408

Title: "Novel Heparin-Induced CCN-Like Molecules

and Uses Therefor"

Inventor: John J. Castellot, Jr. Filing Date: December 7, 2001 Attorney Docket No. MBI-004CN

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

- Response to Restriction Requirement Pursuant to 35 U.S.C. §121 (2 pages);
- Request for One-Month Extension of Time (1 page, in duplicate); and
- Pre-paid Acknowledgment Postcard.

No additional costs are believed to be due in connection with the filing of this Response. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

Express Mail" mailing label number <u>EV 355 388 407 US</u>	Respectfully submitted,
Date of Deposit July 1, 2003	LAHIVE & COCKFIELD, LLP
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Post Office Box 1450, Alexandria, VA 22313-1450.  Amy E. Mandragouras, Esq.  Reg. No. 36,207	Amy E. Mandragouras, Esq. Registration No. 36,207 Attorney for Applicants



In February In John J. Castellot, Jr.

U.S. Serial No.: 10/010,408

Filed: December 7, 2001

For: Novel Heparin-Induced CCN-Like Molecules

And Uses Therefor

Attorney Docket No.: MBI-004CN

Group Art Unit: 1631

Examiner: James Martinell

Plunkett M15/03

**RECEIVED** 

JUL 0 9 2003

**TECH CENTER 1600/2900** 

Commissioner for Patents Post Office Box 1450 Alexandria, VA 22313-1450

"Express Mail" mailing label number	EV 355 388 407 US
Date of Deposit	July 1, 2003
"Express Mail Post Office to Addressee" se	rvice under 37 CFR 1.10 on the date indicated above atents, Post Office Box 1450, Alexandria, VA
Please Print Name of Person Signing	

## RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 U.S.C. §1.21

## Dear Sir:

This is in response to an Office Action (Paper No. 7) dated May 2, 2003. A separate petition for the appropriate extension of time to respond is being filed concurrently herewith.

The Examiner has required restriction to one of the following inventions under 35 U.S.C. §121:

- I. Claims 1-21, 48-50, 58, and 60, drawn to polynucleotides, vectors, host cells, and methods for producing proteins, and methods for detecting nucleic acids, classified in class 536, subclass 23.5 and class 435, subclasses 320.1, 325, 252.3, 69.1, and 6.
- II. Claims 22 and 23 drawn to non-human transgenic animals, classified in class 800, subclass 13.

- III. Claims 24-34 and 38, drawn to proteins and pharmaceutical compositions, classified in class 530, subclass 350 and class 514, subclass 12.
- IV. Claims 35-37 and 39, drawn to antibodies and pharmaceutical compositions, classified in class 530, subclass 387.1 and class 424, subclass 130.1
- V. Claims 40-42, 45, 53, 54, 56, 57, 62, and 63, drawn to methods for modulating cell-associated activity using polypeptides, classified in class 514, subclass 12.
- VI. Claims 40, 43, 45, 47, 53, and 55-57, drawn to methods for modulating cell-associated activity using polynucleotides, classified in class 514, subclass 44.
- VII. Claims 40, 44, and 45, drawn to methods for modulating cell-associated activity using antibodies, classified in class 514, subclass 2.
- VIII. Claim 46, drawn to methods for treating subjects using a modulator of undisclosed nature, classified in class unknown, subclass unknown.
- IX. Claims 48, 51, and 52, drawn to methods for detection of proteins, classified in class 435, subclass 7.1.
- X. Claim 61 drawn to methods of isolating a protein, classified in class 530, subclass 344.

Applicant hereby elects **the Group I invention** (Claims 1-21, 48-50, 58, and 60) for prosecution in this application, *without traverse*.

Applicant reserves the right to traverse the restriction between the non-elected groups in this or a separate application.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 12-0080, under Order No. MBI-004CN from which the undersigned is authorized to draw.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP

28 State Street Boston, MA 02109 Tel.: (617) 227-7400

Dated: July 1, 2003

Amy E. Mandragouras, Esq. Registration No. 86,207

Registration No. 86,207 Attorney for Applicants